Bris­tol-My­ers dodges a bul­let as PT­AB turns down in­ter partes re­view pitch for Cel­gene's cash cow

Cel­gene just won an­oth­er cru­cial patent skir­mish in its on­go­ing fight to keep its block­buster rev­enue pump­ing in from Revlim­id — a key fea­ture in the shaky $74 bil­lion buy­out deal that Bris­tol-My­ers Squibb has been de­fend­ing in a se­ries of ap­pear­ances over the last few days.

The Patent Tri­al and Ap­peal Board has de­nied a pe­ti­tion from Alvo­gen for an in­ter partes re­view of the Revlim­id patents. That move comes a month af­ter Dr. Red­dy’s was al­so stiff armed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER